Among children hospitalized with COVID-19 who received remdesivir, most patients only experienced mild transaminitis and normal creatinine concentrations. The use of remdesivir for the treatment of ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.